Notice Regarding the Revisions of Full-Year Financial Results Forecastfor the Fiscal Year Ending December 31, 202512/11TDnetPDF(143KB)
Non-consolidated Financial Results for the Twelve Months Ended October 31, 2025 (Under Japanese GAAP)12/11TDnetPDF(236KB)
Completion of 30-day review for clinical trial notification for Phase I/II study of HS-005 (catheter administration) 11/4TDnetPDF(322KB)
Supplemental comments regarding termination of partnership with Novo Nordisk AS (#3)10/2TDnetPDF(114KB)
Notice of submission of clinical trial notification for Phase I/II study of HS-005 targeting severe HF due to IHD and DCM10/2TDnetPDF(96KB)
Supplemental comments regarding termination of partnership with Novo Nordisk AS (#2)10/1TDnetPDF(125KB)
Notice regarding the new partner for delivery catheter system for allogeneic iPS cell-derived cardiomyocyte spheroids9/11TDnetPDF(349KB)
Non-consolidated Financial Results for the Nine Months Ended July 31, 2025 (Under Japanese GAAP)9/11TDnetPDF(291KB)
Notice Regarding the Revisions of Full-Year Financial Results Forecast for the Fiscal Year Ending December 31, 20258/14TDnetPDF(190KB)
Non-consolidated Financial Results for the Six Months Ended April 30, 2025 (Under Japanese GAAP)6/12TDnetPDF(330KB)